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Abstract 
Background: Chemotherapy‑induced nausea and vomiting adversely affects the quality of life of patients who 
receive chemotherapy via intravenous infusion or transcatheter arterial chemoembolization (TACE). This study aimed 
to investigate the clinical effects of transcutaneous electrical acupoint stimulation (TEAS) on nausea and vomiting 
after TACE.
Methods: A total of 142 patients who received TACE with cisplatin for primary or metastatic liver cancer were 
assigned to the active‑acupuncture (n = 72) or placebo‑acupuncture (n = 70) groups using a covariate‑adaptive 
randomization at a ratio of 1:1. The acupoints Hegu (LI4), Neiguan (P6), and Zusanli (ST36) were stimulated twice daily 
for 6 days. The effects of TEAS on nausea and vomiting were assessed by using occurrence rate and severity of these 
symptoms. Anorexia scale and M. D. Anderson Symptom Inventory (MDASI) scores were secondary endpoints and 
were used to assess the effect of TEAS on patient appetite and quality of life. The safety of the treatments was also 
monitored.
Results: Between the two groups, the differences in occurrence rates and severities of nausea and vomiting after 
TACE were not significant (all P > 0.05). From the second day after TACE, anorexia scores were significantly lower in the 
active‑acupuncture group than in the placebo‑acupuncture group and continued to decrease over time with treat‑
ment (all P values less than 0.01). On days 0, 1, and 2, the mean MDASI scores for the active‑acupuncture group were 
slightly lower than those for the placebo‑acupuncture group, but the differences were not statistically significant (all 
P > 0.05). No significant differences were found between the two groups in the occurrence rate of any adverse event 
(P > 0.05).
Conclusion: TEAS appears to be a safe and effective therapy to relieve patients’ gastrointestinal discomfort after 
chemotherapy.
Trial registration NCT01895010. Registered 21 June 2013
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Background
Transcatheter arterial chemoembolization (TACE) is a 
palliative treatment of advanced primary and metastatic 
liver cancer. However, chemotherapy-induced nausea 
and vomiting (CINV) adversely affects the quality of life 
(QoL) of patients who undergo this intervention. It is 
estimated that 70%–80% of cancer patients who received 
chemotherapy developed CINV, and nausea and vomit-
ing is one of the most debilitating symptoms induced by 
chemotherapy [1, 2]. Severe vomiting can cause dehy-
dration, electrolyte disturbances, muscle weakness, and 
weight loss; it may even be life-threatening by inducing 
acute hemorrhage of the upper digestive tract. CINV 
drastically lowers QoL and treatment compliance, and it 
may also affect the success of a specific treatment proto-
col [3].
Despite improvements in the prevention and treatment 
of CINV, including the use of type 3 serotonin (5-HT3) 
receptor antagonists [4, 5], there are still potential risks 
of adverse effects [1, 2]. Therefore, the need for further 
relief has led to an interest in non-pharmacological 
therapies [6, 7]. Previous studies have demonstrated the 
efficacy of acupuncture, which has been used for more 
than 2500 years in traditional Chinese medicine to cure 
disease and relieve accompanying symptoms [8–10]. In 
1979, acupuncture was approved by the World Health 
Organization for the treatment of nausea and vomiting 
resulted from disordered function of the stomach [11]. 
Some randomized clinical trials have found that acu-
puncture is an effective palliative treatment of cancer 
patients, especially for reducing chemotherapy-induced 
adverse effects such as nausea and vomiting [12]. Trans-
cutaneous electrical acupoint stimulation (TEAS) is an 
electrical stimulation technique that sends electrical 
impulses into acupoints through electrodes on the skin 
surface. TEAS is noninvasive, is easy to use, and does not 
have obvious adverse effects.
Although noninvasive electro-acupuncture has been 
shown to benefit patients suffering from CINV [13–15], 
studies on TEAS combined with anti-emetics, particu-
larly in patients with refractory symptoms or receiv-
ing highly emetogenic chemotherapy drugs, are needed 
to determine if this regimen is also safe and effective 
to relieve patients’ gastrointestinal discomfort after 
chemotherapy [16]. In our previous study, we found 
that electro-stimulation on the acupoint Yongquan (K1) 
combined with anti-emetics did not result in initial pre-
vention of cisplatin- or oxaliplatin-induced nausea or 
vomiting [17]. However, it is possible that an extended 
treatment time and the selection of different acupoints 
(particularly in the form of combined points) might 
offer more promising results. Previous studies indicated 
that stimulation on the acupoint Neiguan (P6) was an 
effective anti-emetic technique for the prevention of 
CINV [18, 19], and stimulation on the acupoints Zusanli 
(ST36) and Hegu (LI4) showed similar results [20–23]. 
Stimulation on two or more acupoints may improve 
anti-emetic efficacy, but it lacks the support of clinical 
trial data. In this study, we chose to stimulate the three 
acupoints P6, ST36, and LI4 together as a new regimen, 
which also considered traditional Chinese medicine’s 
“meridian” theory.
In this study, all participants were diagnosed with pri-
mary or metastatic liver cancer, and TACE with cisplatin 
was considered the optimal treatment. Because cispl-
atin is highly emetogenic, we used electrical stimulation 
(active acupuncture vs. placebo acupuncture) combined 
with a 5-HT3 receptor antagonist, palonosetron. Partici-
pants were randomly assigned to the active-acupuncture 
or the placebo-acupuncture group. The acupoints LI4, 
P6, and ST36 were stimulated twice daily for 6 days. The 
effects of TEAS on nausea and vomiting, appetite, and 
QoL were also assessed.
Based on the finding that acupuncture was efficacious 
for the treatment of CINV, we proposed that electri-
cal stimulation would be effective for patients receiving 
TACE. Thus, we designed the present single-blind, rand-
omized, controlled trial to examine the safety and efficacy 
of active acupuncture compared with placebo acupunc-
ture for the treatment of CINV.
Patients and methods
Randomization and blinding
All research procedures were approved by the Institu-
tional Review Board (IRB) of Fudan University Shanghai 
Cancer Center, Shanghai, China (IRB approval number: 
1301118-8-1303), and investigations were conducted in 
accordance with the Consolidated Standards of Report-
ing Trials statement [24] and the 2010 Standards for 
Reporting Interventions in Clinical Trials of Acupunc-
ture [25]. The study protocol was registered on Clinical-
Trials.gov (Identifier: NCT01895010).
We included all patients at least 18 years old, with pri-
mary or metastatic liver cancer and planned to receive 
cisplatin-based TACE. None of them was receiving other 
acupuncture therapy. The skin of acupoint site receiv-
ing electrical acupoint stimulation must be intact and 
without visible evidence of injury and can tolerate mild 
discomfort following electrical stimulation. Exclusion 
criteria were as follows: (1) combined use of other venous 
chemotherapy within 5  days after TACE; (2) other con-
founding factors that may cause nausea and vomiting 
(such as intestinal obstruction, anorexia, and so on); (3) 
installing pacemaker; (4) cognitive dysfunction, unable to 
finish Scale; or (5) TEAS treatment within the past year 
regardless of indication.
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Patients enrolled in this study were assigned into an 
active-acupuncture group or a placebo-acupuncture 
group, using covariate-adaptive randomization (or mini-
mization) at a ratio of 1:1. This randomization was used 
to avoid covariate imbalances resulting from simple ran-
domization, owing to the fact that this was a small study 
[26]. The study was designed as single-blind, in which the 
random codes and corresponding treatment measures 
were known only by the acupuncturist (F.J.). Patients, 
nurses, researchers, and the principal investigators were 
unaware of the randomization scheme. Patients who did 
not receive electrical acupoint stimulation were not told 
during assignment about the potential responses of the 
control and electro-acupuncture procedures.
Patients
This study was conducted in the Department of Integra-
tive Oncology, Fudan University Shanghai Cancer Center, 
Shanghai, China. All patients received TACE with cispl-
atin for primary or metastatic liver cancer between Janu-
ary 2012 and December 2014. Investigators explained 
the research to the patients in detail and answered ques-
tions, and patients were informed about the study design, 
including the use of active and placebo acupuncture, as 
well as the possible adverse effects of anti-emetic drugs 
(constipation, headache, and dizziness) and acupuncture 
treatment (uncomfortable feelings of the skin). Patients 
were enrolled in the study if they met all the inclusion 
criteria and did not fall under any exclusion criteria. 
Enrolled patients were required to maintain close contact 
with the researchers.
Interventions
To treat liver lesions, all patients underwent one TACE 
treatment with cisplatin (60  mg) as the main drug. The 
TACE procedure took 0.5–1.0 h. The chemotherapy regi-
men did not include steroids. Before the TACE proce-
dure, all patients received the 5-HT3 receptor antagonist 
palonosetron hydrochloride (0.25 mg, intravenous injec-
tion) to prevent vomiting. Then, the patients received the 
randomized intervention: active or placebo acupuncture. 
On the first day, patients in the active-acupuncture group 
received the first electrical stimulation 1–2  h before 
TACE and another stimulation just after TACE. Acu-
puncture was continued twice daily for 5 consecutive 
days, for a total of 6 days.
Patients were asked to adopt a comfortable sitting or 
supine position. The acupoints were wiped with a moist 
cotton swab and then connected to the anode and cath-
ode of the electrical stimulation generator (Yao Yang 
Kang Da Company, Shanghai, China) through an elec-
trode patch placed on the skin surface. Continuous wave-
form mode was selected, and then the electric current 
produced continuous stimulation on the acupoints. 
Stimulation frequency was set at 4  Hz [27], and the 
default value was set as 10 mA, which was twice the sen-
sory threshold (5 mA). The intensity was adjusted every 
10  min to keep the patients comfortable, and its actual 
value ranged from 7 to 15  mA [27]. Each acupuncture 
treatment took 30 min.
Acupoints included were as follows. (i) Neiguan (P6): 
located 6 cm above the transverse crease of the wrist and 
between the palmaris longus tendon and the tendon of 
flexor carpi radialis; (ii) Zusanli (ST36): located below the 
knee, on the anterior tibialis muscle, along the stomach 
meridian; and (iii) Hegu (LI4): located on the dorsum of 
the hand, between the first and second metacarpal bones, 
approximately in the middle of the second metacarpal 
bone on the radial side.
In the placebo-acupuncture group, the electrodes 
were placed on the same acupoints and treated for the 
same duration as in the active-acupuncture group, but 
the intensity of electric stimulation was 0  mA. During 
treatment sessions, patients were allowed to watch the 
operation of the electrical stimulator and view the entire 
procedure. They could watch the doctor set the acupoint 
stimulation equipment at 4  Hz and press the start but-
ton. Therefore, all patients thought they received real 
electro-acupuncture.
Chemotherapy, palonosetron, and additional anti-
emetics were given by an independent staff physician, 
who was blinded to the acupuncture treatment. As pre-
scribed by the staff physician, the following rescue anti-
emetics were administered: palonosetron (0.25  mg), 
metoclopramide (10 mg), and steroids (5 mg).
Outcome measurement
Every day, patients were required to fill out nausea and 
vomiting diary records to document the severity and fre-
quency of nausea and vomiting. Visual analogue score 
(VAS) of anorexia is a secondary clinical outcome that 
measures appetite improvement. VAS ranges from 0 
(normal appetite) to 10 (no food intake possible) [28]. 
In addition, the M. D. Anderson Symptom Inventory 
(MDASI) [29] was used to assess the effect of CINV on 
a patient’s QoL. Adverse events were recorded during 
treatment and at follow-up visits. Some events, such as 
constipation, headache, and dizziness, could be related 
to the anti-emetic drugs. Other events, such as tingling, 
pain, or redness where the electrode contacted the skin, 
could be related to acupuncture treatment.
Statistical analysis
Statistical analysis was performed by a statistician from 
the Department of Statistics, Fudan University Shanghai 
Cancer Center who was blinded to treatment allocation. 
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Data analysis of baseline characteristics was based on 
the intention-to-treat population, which included all 
randomly assigned patients. Baseline demographic and 
clinical variables of the two groups were compared using 
Student’s t test (continuous variables) or the Chi square 
test (categorical variables). Efficacy analyses were based 
on observed patients who completed both baseline and 
endpoint evaluation. To determine clinical response, the 
primary outcome variable was analyzed using the Chi 
square test. Secondary outcome variables, including ano-
rexia VAS and MDASI score, were analyzed in the form 
of a descriptive comparison using Student’s t test. For 
adverse events, we compared the occurrence rates using 
Fisher’s exact test. P values less than 0.05 (two-sided) 
were considered statistically significant. All analyses were 




Of 164 patients with liver cancer who received TACE 
at our institution between January 2012 and Decem-
ber 2014, 22 either did not meet the inclusion criteria 
or did not consent to participate. The study was con-
ducted according to the protocol, and the remaining 
142 patients completed the study. These 142 patients 
were randomly assigned to the active-acupuncture treat-
ment group (n = 72) or the placebo-acupuncture group 
(n = 70) (Fig. 1). No significant differences were observed 
between the two groups in terms of baseline characteris-
tics (Table 1).
Efficacy
Changes in occurrence rate and severity of nausea and 
vomiting from the first acupuncture treatment over time 
are illustrated in Tables  2 and 3. Although fewer patients 
suffered from nausea and vomiting on days 0, 1, 2, 4, and 
5 in the active-acupuncture group than in the placebo-
acupuncture group, the difference was not significant (all 
P > 0.05) (Fig. 2). On days 0, 2, and 4, we observed fewer 
patients with severe or intolerable vomiting in the active-
acupuncture group than in the placebo-acupuncture group; 
and on days 0 and 2, we observed fewer patients with severe 
to intolerable nausea in the active-acupuncture group than 
in the placebo-acupuncture group. However, the differ-
ences were not statistically significant (all P > 0.05).
The mean anorexia VAS increased after TACE treat-
ment until the third treatment of nausea and vomiting 
after TACE in the placebo-acupuncture group. However, 
in the active-acupuncture group, the anorexia VAS began 
to decrease after the first day and continued to decrease 
with treatment over time. From the second day after 
TACE, the anorexia VAS was significantly lower in the 
active-acupuncture group than in the placebo-acupunc-
ture group (P = 0.008, 0. 004, 0.005, and 0.002 on days 2, 
3, 4, and 5, respectively; Fig. 2).
Patients rated themselves on the MDASI to evalu-
ate the effect on QoL and activities in daily living. On 
days 0, 1, and 2, the mean MDASI score for the active-
acupuncture group was slightly lower than that for the 
placebo-acupuncture group, but the differences were not 
statistically significant (all P > 0.05) (Fig. 2).
Safety and tolerability
No serious adverse events occurred in either group 
(Table  4). Two incidents of mild tingling or redness 
where the electrode contacted the skin were reported in 
the active-acupuncture group. All patients’ symptoms 
resolved once the acupuncture treatment was completed. 
However, to avoid further damage, patients were still 
told to apply ice and compression within 6  h after the 
acupuncture treatment. Eight patients in the active-acu-
puncture group and ten patients in the placebo-acupunc-
ture group complained of mild or moderate constipation. 
Laxative drugs were administrated to relieve patient 
symptoms. Five patients in the active-acupuncture group 
and four patients in the placebo-acupuncture group 
experienced headache during the treatment, which was 
most likely an adverse effect of palonosetron. No sig-
nificant differences in the occurrence rate of any adverse 
events were found between the two groups (all P > 0.05) 
(Table 4).
Credibility of placebo and acupuncture procedures
No significant differences were observed in the credibility 
rating between the two groups. Thirty percent (21/70) of 
patients treated with placebo acupuncture thought they 
had received active acupuncture, whereas 19.4% (14/72) 
of patients treated with active acupuncture thought they 
had received placebo treatment (χ2 = 2.13, P = 0.145).
Enrollment





















Fig. 1 Flow chart of patient inclusion
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Discussion
We found no significant effect of TEAS in reducing 
CINV or improving QoL. However, electrical stimula-
tion on acupoints LI4, P6, and ST36 did markedly relieve 
appetite loss from the second day after TACE.
CINV is typically associated with a high level of 5-HT, 
which activates 5-HT3 receptors to stimulate vomiting 
centers. The introduction of 5-HT3 receptor antagonists 
led to significant improvements in the control of acute 
nausea and vomiting, and 5-HT3 receptor antagonists are 
now part of the standard regimen. However, a substan-
tial proportion of patients continue to experience both 
acute and delayed CINV after moderately or highly eme-
togenic chemotherapy. Additionally, adverse events such 
as headache, constipation, abdominal pain, and dizziness 
may cause discomfort to patients [4, 30]. Palonosetron 
is a highly potent, second-generation, selective 5-HT 
receptor antagonist. One study showed that palonose-
tron hydrochloride reduced the occurrence rate of acute 
nausea and vomiting after highly emetogenic chemother-
apy by 59.2% [4]. However, even if such a prophylactic 
approach is taken, sudden nausea and vomiting may still 
occur. Furthermore, the effectiveness of palonosetron 
hydrochloride for delayed vomiting remains unsatisfac-
tory, with a reported occurrence rate of 45.3% at a dosage 
of 0.25 mg and 48.0% at a dosage of 0.75 mg [4]. Repeated 
administration did not improve results but did increase 
potential adverse effects and medical expenses. There-
fore, to achieve better anti-emetic effects, palonosetron 
should be combined with other treatment approaches.
Electro-acupuncture was found to be effective in treat-
ing moderate CINV [31], with needles inserted into 
acupoints on the body, which were then attached to a 
device that generates continuous electric pulses using 
small clips. Electro-acupuncture might result in compli-
cations such as needle syncope, pain, and organ punc-
ture. Furthermore, traditional electro-acupuncture 
using needles is not always convenient or available in 
all centers. TEAS is a novel and noninvasive method of 
acupuncture that has a similar mechanism of action to 
electro-acupuncture and is considered a safe and effec-
tive treatment.
In our study, all patients were successfully blinded and 
completed the entire study. The credibility rating in the 
two groups did not differ significantly. Acute CINV usu-
ally occurs within the first 24 h after drug administration, 
and most emetic chemotherapy drugs can trigger nausea 
and vomiting within 1 or 2 h after drug administration. In 
contrast, delayed CINV occurs 24 h after drug adminis-
tration and may last for 6–7 days. Our present study sug-
gested that electrical stimulation on acupoints, combined 
with 5-HT3 receptor antagonists, could slightly reduce 
the occurrence rate of nausea and vomiting on day 0 and 
subsequent days (except on day 3), but the therapeutic 
efficacy was not significant compared with that of the 
placebo treatment (P  >  0.05). Similarly, no significant 
differences were observed between the two groups with 
regard to the degree of nausea or vomiting on days 0–5. 
This indicates that electro-stimulation of the combined 
acupoints was not efficacious in augmenting the anti-
emetic effects of 5-HT3 receptor antagonists in prevent-
ing acute or delayed CINV.
One possible reason why the treatment of more acu-
points did not increase the anti-emetic effects more 
Table 1 Baseline demographic and clinical characteristics of patients with nausea and vomiting after treated with tran-
scatheter arterial chemoembolization (TACE)
VAS visual analogue score
a These data are presented as median followed by range in parentheses
b These values are presented as mean ± standard deviation; other values are presented as number of patients followed by percentage in parentheses
Characteristic Placebo-acupuncture group Active-acupuncture group P
(n = 70) (n = 72)
Age (years)a 57.5 (30–75) 55.4 (41–77) 1.000
Sex 0.768
 Men 47 (67.1) 50 (69.4)
 Women 23 (32.9) 22 (30.6)
Diagnosis 0.492
 Primary liver cancer 15 (21.4) 19 (26.4)
 Metastatic liver cancer 55 (78.6) 53 (73.6)
Chemotherapy 1.000
 Cisplatin‑based regimen 70 (100) 72 (100)
 Non‑cisplatin‑based regimen 0 (0) 0 (0)
VAS of anorexiab 1.50 ± 1.67 1.79 ± 1.82 0.321
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than a regimen that treated only a single acupoint may 
be that most of the studies reported of these single-
acupoint regimens were based on electro-acupuncture 
with the insertion of needles into the skin, rather than 
TEAS, which was used in our study. According to a 
meta-analysis by Ezzo et  al. [16], acupressure or sur-
face electro-stimulation may have weaker effects than 
electro-acupuncture with needles. However, to our 
knowledge, the electro-stimulation mechanism of multi-
ple acupoints remains unclear, and related fundamental 
research is needed.
Although our study did not reach its primary end-
point, TEAS was shown to be effective in recovering 
patient appetites after chemotherapy, as indicated by the 
significant decrease of the anorexia VAS. The effect was 
observed as early as the first day after TACE, and the 
decrease of VAS was greater in the active-acupuncture 
group than in the placebo-acupuncture group. These 
results were in agreement with previous studies that 
demonstrated the therapeutic effects of acupuncture in 
patients with chemotherapy- or radiotherapy-induced 
anorexia [32–34]. Acupuncture may stimulate the stom-
ach’s peristalsis and rapidly empty its contents, thus 
strengthening gastrointestinal motility and resulting in 
a sense of hunger [35]. This is the most effective way to 
rapidly improve the appetite; some patients even have a 
sense of hunger just 1 min after acupuncture. During the 
early stage of nausea, loss of appetite and feelings of dis-
comfort are the major clinical manifestations. Based on 
our findings and those of previous reports, we think that 
a rapid improvement of appetite brought about by TEAS 
indicates an early sign of recovered gastrointestinal func-
tion. Furthermore, a rapid improvement of appetite can 
help improve patients’ entire recovery process, by reduc-
ing sodium electrolyte and energy metabolism disorders, 
by resulting in weight gain through an increase in food 
intake, and by improving the emotional state of patients 
and family members.
The frequency of adverse events in both groups was 
similar, and only two TEAS-treated patients complained 
of discomfort at the electrode patch site, which might 
be related to the acupuncture treatment. Therefore, the 
treatment was well tolerated and safe.
In summary, our study used combined acupoints 
P6, LI4, and ST36 rather than a single acupoint to treat 
CNIV. Although the occurrence rates of nausea and 
vomiting did not significantly decrease for patients with 
primary liver cancer who were treated with TACE, the 
anorexia VAS was significantly lower in the active-acu-
puncture group than in the placebo-acupuncture group, 
starting from the second day after TACE. The acupunc-
ture treatment is low in cost, has few adverse reactions, 
and is simple to administer. Acupuncture may be an 
optional adjunctive treatment for palliative care; further 
studies using TEAS are warranted.
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Fig. 2 Comparison between active‑acupuncture and placebo‑
acupuncture groups. a anorexia VAS; b MDASI score over time. TACE 
transcatheter arterial chemoembolization; VAS visual analogue score; 
MDASI M. D. Anderson Symptom Inventory
Table 4 Occurrence rate of  adverse events in  the active-
acupuncture and placebo-acupuncture groups








Constipation 10 (14.2) 8 (11.1) 0.570
Headache 4 (5.7) 5 (6.9) 1.000
Mild tingling or redness of 
the contact part of the skin
0 (0) 2 (2.8) 0.497
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